MetaVia Inc. Files 8-K: Regulation FD & Financials
Ticker: MTVA · Form: 8-K · Filed: Aug 6, 2025 · CIK: 1638287
| Field | Detail |
|---|---|
| Company | Metavia INC. (MTVA) |
| Form Type | 8-K |
| Filed Date | Aug 6, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financials, corporate-history
Related Tickers: MTVA
TL;DR
MetaVia Inc. (MTVA) filed an 8-K for Reg FD and financials. Formerly NeuroBo and Gemphire.
AI Summary
On August 6, 2025, MetaVia Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. MetaVia Inc. was formerly known as NeuroBo Pharmaceuticals, Inc. and Gemphire Therapeutics Inc., with name changes occurring on December 31, 2019, and March 31, 2015, respectively. The company is incorporated in Delaware and headquartered in Cambridge, Massachusetts.
Why It Matters
This 8-K filing provides updates on MetaVia Inc.'s regulatory disclosures and financial statements, which are crucial for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, not indicating any immediate operational or financial distress.
Key Players & Entities
- MetaVia Inc. (company) — Registrant
- NeuroBo Pharmaceuticals, Inc. (company) — Former company name
- Gemphire Therapeutics Inc. (company) — Former company name
- 20191231 (date) — Date of name change
- 20150331 (date) — Date of name change
- August 6, 2025 (date) — Date of report
FAQ
What specific information is being disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the provided text snippet.
What types of financial statements and exhibits are included in this filing?
The filing states 'Financial Statements and Exhibits' are included, but the specific nature or content of these documents is not detailed in the provided text.
When did MetaVia Inc. change its name from NeuroBo Pharmaceuticals, Inc.?
MetaVia Inc. changed its name from NeuroBo Pharmaceuticals, Inc. on December 31, 2019.
What was MetaVia Inc.'s previous name before NeuroBo Pharmaceuticals, Inc.?
Before being known as NeuroBo Pharmaceuticals, Inc., the company was named Gemphire Therapeutics Inc.
Where is MetaVia Inc.'s principal executive office located?
MetaVia Inc.'s principal executive offices are located at 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on August 6, 2025 regarding MetaVia Inc. (MTVA).